Comments on: Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development

Comments on: Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development https://www.worldpharmatoday.com/clinical-trails/novartis-discontinues-asa404-clinical-trial-program-and-shifts-focus-to-other-cancer-compounds-in-early-and-late-stage-development/ Magazine for the C-level Pharma Executives Wed, 10 Nov 2010 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4